Loading...
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.
Senkus-Konefka, E Domchek, S Im, S Xu, B Armstrong, Anne C Masuda, N Delaloge, S Li, W Tung, N Conte, P
Senkus-Konefka, E
Domchek, S
Im, S
Xu, B
Armstrong, Anne C
Masuda, N
Delaloge, S
Li, W
Tung, N
Conte, P
Citations
Altmetric:
Abstract
Description
Date
2018-04
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. 2018, 92:.S19 Eur J Cancer